SA, et al: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935–1945.
22D’Incecco A, et al: PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95–102.
23Velcheti V, et al: Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107–116.
24Li X, et al: Emerging immune checkpoints for cancer therapy. Acta Oncol 2015;54:1706–1713.
25Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630–641.
26Joura EA, et al: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711–723.
27Janakiram NB, et al: Prophylactic vaccine approach for colon and pancreatic cancers: present and future. Curr Med Chem 2012;19:3664–3678.
28Watson CJ, Gusterson BA: A prophylactic vaccine for breast cancer? Breast Cancer Res 2010;12:310.
29Feyerabend S, et al: Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917–927.
30Kirner A, Mayer-Mokler A, Reinhardt C: IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother 2014;10:3179–3189.
31Higano CS, et al: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670–3679.
32Wei XX, Fong L, Small EJ: Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines 2015;14:1529–1541.
33Perez P, et al: Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354–356.
34Sadelain M, Brentjens R, Riviere I: The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388–398.
35Maude SL, et al: CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017–4023.
36Sim GC, Radvanyi L: The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev 2014;25:377–390.
37Xu HM: Th1 cytokine-based immunotherapy for cancer. Hepatobiliary Pancreat Dis Int 2014;13:482–494.
38Dillman RO, et al: Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 2012;27:337–343.
39Rosenberg SA: IL-2: the first effective immunotherapy for human cancer. J Immunol 2014;192:5451–5458.
40Letourneau S, et al: IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA 2010;107:2171–2176.
41Cohen J: IL-12 deaths: explanation and a puzzle. Science 1995;270:908.
42Fallon J, et al: The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 2014;5:1869–1884.
43Schliemann C, et al: Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009;113:2275–2283.
44Straub JM, et al: Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol 2015;141:1985–1994.
45Morris JC, et al: Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 2014;9:e90353.
46Moran AE, Kovacsovics-Bankowski M, Weinberg AD: The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013;25:230–237.
47Shi M, et al: Application potential of toll-like receptors in cancer immunotherapy: systematic review. Medicine (Baltimore) 2016;95:e3951.
48Braumuller H, et al: T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361–365.
49Wolchok JD, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412–7420.
50Michot JM, et al: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–148.
51Demaria S, Formenti SC: Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012;2:153.
52Dudek AM, et al: Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013;24:319–333.
53Galluzzi L, Kepp O, Kroemer G: Immunogenic cell death in radiation therapy. Oncoimmunology 2013;2:e26536.
54Golden EB, Apetoh L: Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015;25:11–17.
55Kepp O, et al: Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014;3:e955691.
56Reits EA, et al: Radiation
